Reactive astrogliosis in the context of Alzheimer’s disease (AD) has been the subject of extensive research and it is widely acknowledged as a highly complex process. Mona-Lisa Malarte, PhD Candidate, Center of Alzheimer Research, Karolinska Institutet, Stockholm, Sweden, discusses the use of PET tracers to aid our understanding of reactive astrogliosis. This process involves a family of highly heterogenous astrocytes, which can exhibit diverse morphological, molecular, and functional characteristics. Their behavior can be region-specific within the brain and may vary in response to different pathological conditions and disease severities. The use of highly specific PET tracers can aid in the localization and quantification of reactive astrogliosis biomarkers. This can help to better understand the subtypes of astrocytes involved in this process and how they contribute to AD. However, further investigation is required to understand exactly how the tracers interact with their target, how specific they are, and the clinical relevance of reactive astrogliosis measures along the disease continuum. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.